Theofanis Mitsinikos, DO
Endocrinology, Diabetes & Metabolism · Stony Brook, NYNPI 1467624064
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 21.8%. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,458 payments — averaging $107.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$34K
- Mannkind Corporation$24K
- AbbVie$22K
- Intra-sana Laboratories$14K
- Sanofi-aventis U.S. LLC$13K
- Amarin Pharma, Inc.$13K
- plus $37K from 54 others
What the payments were for
- Consulting fees$18,45112%
- Speaking & faculty fees$93,66560%
- Travel & lodging$3,3652%
- Food & beverage$41,14726%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$32,655
- AFREZZA$21,940
- Synthroid$20,685
- Vascepa$10,866
- Reltone 200 Mg$8,739
- GLYCATE$8,739
- Reltone 400 Mg$8,739
- TZIELD$7,271
- Pogo Automatic Blood Glucose Monitoring System$6,774
- ZEPBOUND$4,783
- DISEASE STATE$2,653
- INVOKANA$2,340
- Tirosint$2,225
- LOKELMA$642
- Barostim Neo System$569
- KRYSTEXXA$501
- SOLIQUA 100/33$493
- Yorvipath$390
- DEXCOM G6 TRANSMITTER$369
- JARDIANCE$359
How this compares
$156,731 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 291 | $672,885 |
| TrulicityDulaglutide | 294 | $596,802 |
| FarxigaDapagliflozin Propanediol | 266 | $400,072 |
| MounjaroTirzepatide | 214 | $321,307 |
| JardianceEmpagliflozin | 141 | $239,933 |
| Bydureon BciseExenatide Microspheres | 106 | $217,063 |
| Xigduo XrDapaglifloz Propaned/Metformin | 126 | $156,791 |
| ProliaDenosumab | 90 | $154,939 |
| VascepaIcosapent Ethyl | 108 | $104,906 |
| JanuviaSitagliptin Phosphate | 64 | $101,717 |
| SynthroidLevothyroxine Sodium | 766 | $68,703 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $65,373 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $64,755 |
| Cinacalcet Hcl | 41 | $63,543 |
| AfrezzaInsulin Regular, Human | 40 | $56,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $6,681 | $921,812523 claims |
| Novo NordiskOzempic, Novolog | $3,010 | $680,827306 claims |
| AstraZenecaFarxiga | $34,150 | $400,072266 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy | $1,683 | $342,729207 claims |
| MerckJanuvia, Janumet Xr, Janumet | $225 | $173,288118 claims |
| AmgenProlia | $2,748 | $154,93990 claims |
| AbbVieSynthroid | $22,208 | $68,703766 claims |
| Mannkind CorporationAfrezza | $23,966 | $56,50040 claims |
| BayerKerendia | $755 | $45,46724 claims |
| Johnson & JohnsonInvokana | $2,472 | $36,29623 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $553 | $11,075669 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Stony Brook
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.